Diabetic Nephropathy - Pipeline Review, H1 2016

Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Diabetic Nephropathy Overview 10
Therapeutics Development 11
Pipeline Products for Diabetic Nephropathy - Overview 11
Pipeline Products for Diabetic Nephropathy - Comparative Analysis 12
Diabetic Nephropathy - Therapeutics under Development by Companies 13
Diabetic Nephropathy - Therapeutics under Investigation by Universities/Institutes 16
Diabetic Nephropathy - Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Unknown Stage Products 20
Diabetic Nephropathy - Products under Development by Companies 21
Diabetic Nephropathy - Products under Investigation by Universities/Institutes 25
Diabetic Nephropathy - Companies Involved in Therapeutics Development 26
AbbVie Inc. 26
Antisense Therapeutics Limited 27
Arena Pharmaceuticals, Inc. 28
Astellas Pharma Inc. 29
AstraZeneca Plc 30
Bayer AG 31
BiOrion Technologies B.V. 32
BoehringerIngelheim GmbH 33
Cellmid Limited 34
ChemoCentryx, Inc. 35
Concert Pharmaceuticals, Inc. 36
CSL Limited 37
Daiichi Sankyo Company, Limited 38
Dimerix Bioscience Pty Ltd 39
Dong Wha Pharma Co., Ltd. 40
Dynamis Therapeutics, Inc. 41
Eli Lilly and Company 42
Galectin Therapeutics, Inc. 43
GenKyoTex S.A. 44
Gilead Sciences, Inc. 45
GlaxoSmithKline Plc 46
Glucox Biotech AB 47
GNI Group Ltd. 48
Islet Sciences, Inc. 49
Jenrin Discovery, Inc. 50
Johnson & Johnson 51
Mallinckrodt Plc 52
Mesoblast Limited 53
Mitsubishi Tanabe Pharma Corporation 54
MorphoSys AG 55
NephroGenex, Inc. 56
Noxxon Pharma AG 57
Omeros Corporation 58
Otsuka Holdings Co., Ltd. 59
Pfizer Inc. 60
PhytoHealth Corporation 61
ProMetic Life Sciences Inc. 62
Serodus ASA 63
Shire Plc 64
Takeda Pharmaceutical Company Limited 65
Theravance Biopharma, Inc. 66
Tobira Therapeutics, Inc. 67
Vascular Pharmaceuticals, Inc. 68
Vicore Pharma AB 69
XOMA Corporation 70
Diabetic Nephropathy - Therapeutics Assessment 71
Assessment by Monotherapy Products 71
Assessment by Target 72
Assessment by Mechanism of Action 75
Assessment by Route of Administration 78
Assessment by Molecule Type 80
Drug Profiles 82
11-RVIVIT - Drug Profile 82
A-717 - Drug Profile 83
Antibodies to Inhibit Heparanase for Cancer - Drug Profile 84
APD-371 - Drug Profile 85
APX-115 - Drug Profile 86
ASP-8232 - Drug Profile 87
ATL-1103 - Drug Profile 88
atrasentan hydrochloride - Drug Profile 90
baricitinib - Drug Profile 91
BI-703704 - Drug Profile 94
Biologic for Diabetic Nephropathy - Drug Profile 95
BOT-191 - Drug Profile 96
C-21 - Drug Profile 97
canagliflozin - Drug Profile 99
CCX-140 - Drug Profile 101
cenicrivirocmesylate - Drug Profile 103
corticotropin - Drug Profile 105
CS-3150 - Drug Profile 107
CSL-346 - Drug Profile 109
CTP-499 - Drug Profile 110
Cyndacel-M - Drug Profile 112
DMX-250 - Drug Profile 114
Drugs to Activate Nrf2 for Diabetic Cardiomyopathy and Metabolic Disorders - Drug Profile 115
DT-23552 - Drug Profile 116
DW-1029M - Drug Profile 117
DYN-12 - Drug Profile 118
emapticappegol - Drug Profile 120
finerenone - Drug Profile 122
gevokizumab - Drug Profile 123
GKT-136901 - Drug Profile 127
GKT-831 - Drug Profile 129
GRMD-02 - Drug Profile 130
GW-610742 - Drug Profile 133
JD-5037 - Drug Profile 134
JNJ-39933673 - Drug Profile 135
Monoclonal Antibodies to Inhibit MASP-2 for Rheumatoid Arthritis and Diabetic Complications - Drug Profile 136
Monoclonal Antibody to Inhibit Midkine for Cancer, Metabolic Disorders and Kidney Diseases - Drug Profile 138
MOR-107 - Drug Profile 140
MPC-300IV - Drug Profile 141
MT-3995 - Drug Profile 143
Nephrilin - Drug Profile 144
oxypurinol - Drug Profile 145
PBI-4050 - Drug Profile 146
PBI-4547 - Drug Profile 148
PF-00489791 - Drug Profile 149
PHN-033 - Drug Profile 150
pirfenidone - Drug Profile 151
probucol - Drug Profile 152
PyridoxamineDihydrochloride - Drug Profile 153
selonsertib - Drug Profile 156
SER-150 - Drug Profile 157
SHP-627 - Drug Profile 159
Small Molecule to Inhibit NOX-4 for Diabetic Nephropathy - Drug Profile 160
Small Molecules for Diabetic Nephropathy - Drug Profile 161
Small Molecules for Ophthalmology, Cardiovascular, CNS and Metabolic Disorders - Drug Profile 162
Small Molecules to Inhibit Heparanase for Metastatic Cancer and Diabetic Nephropathy - Drug Profile 164
SP-20202 - Drug Profile 165
TAK-272 - Drug Profile 166
TAK-648 - Drug Profile 167
TBE-31 - Drug Profile 168
TD-0714 - Drug Profile 169
VPI-2690B - Drug Profile 170
VS-105 - Drug Profile 172
XRX-108 - Drug Profile 173
XRX-221 - Drug Profile 174
Diabetic Nephropathy - Recent Pipeline Updates 175
Diabetic Nephropathy - Dormant Projects 233
Diabetic Nephropathy - Discontinued Products 236
Diabetic Nephropathy - Product Development Milestones 237
Featured News & Press Releases 237
Appendix 245
Methodology 245
Coverage 245
Secondary Research 245
Primary Research 245
Expert Panel Validation 245
Contact Us 245
Disclaimer 246